Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab. METHODS: We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab. The primary end point was progression-free survival. RESULTS: A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone. The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048). There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31). There was a significant interaction between treatment group and KRAS mutation status for tumor response (P=0.03) but not for progression-free survival (P=0.07) or overall survival (P=0.44). The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94), in favor of the cetuximab-FOLFIRI group. The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P<0.001), infusion-related reactions (in 2.5% vs. 0%, P<0.001), and diarrhea (in 15.7% vs. 10.5%, P=0.008). CONCLUSIONS: First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov number, NCT00154102.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sub-analysis revealed that the benefits of cetuximab were limited to patients with KRAS wild-type (wt) tumors.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“The results of this trial demonstrated a decrease in progression-free survival but no difference in overall survival.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“Some large clinical trials have shown that FOLFIRI (leucovorin + 5-FU + irinotecan) or FOLFOX regimens combined with EGFR inhibitors can benefit KRAS-WT CRC.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“However, CRC with KRAS mutations do not benefit from EGFR inhibitors, possibly because activation of KRAS does not depend upstream on EGFR [149,150,151,152].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“According to the CRYSTAL trial, the application of cetuximab and FOLFIRI in first-line treatment can reduce the risk of progression by 15% and increase overall survival (OS) by 8.2 months in patients who have KRAS WT mCRC compared with patients taking FOLFIRI alone [5].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [5]
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Research works printed but not linked: 3
- Rougier P, 2004, J Clin Oncol, 22, 248s, 10.1200/jco.2004.22.14_suppl.3513 · doi:10.1200/jco.2004.22.14_suppl.3513
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Schilsky RL, 2002, Clin Cancer Res, 8, 935
Cited by
Items 601–700 of 1,017
The Tumor Microenvironment in Colorectal Cancer Therapy
Pedrosa, L., Esposito, F., Thomson, T. M., & Maurel, J. (2019) · Cancers · doi:10.3390/cancers11081172 · Cited by 69
“In the last two decades, the use of chemotherapy (CHT) and targeted-agents (TA) has afforded significant progress in survival [29,30].”
BackgroundKhan, K. H., Valeri, N., Dearman, C., Rao, S., Watkins, D. J., Starling, N., Chau, I., & Cunningham, D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.001 · Cited by 75
Sánchez-Martín, F. J., Bellosillo, B., Gelabert-Baldrich, M., Dalmases, A., Cañadas, I., Vidal, J., Martinez, A., Argilés, G., Siravegna, G., Arena, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2400 · Cited by 68
“Approved mAbs directed against the EGFR, cetuximab and panitumumab, provide significant survival benefit to patients with wild-type (WT) KRAS andNRASmetastatic colorectal cancer (MCRC) and are now standard components of treatment regimens for these patients, either alone or in combination with chemotherapy (1, 2).”
BackgroundSelf-citationSuenaga, M., Mizunuma, N., Matsusaka, S., Shinozaki, E., Ozaka, M., Ogura, M., & Yamaguchi, T. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s85567 · Cited by 74
Adelstein, B., Dobbins, T., Harris, C. A., Marschner, I. C., & Ward, R. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.031 · Cited by 75
“Cetuximab or panitumumab was used as first or second line treatment in the nine other studies, in combination with fluoropyrimidines (fluorouracil or capecitabine), with either oxaliplatin or irinotecan.(20,28,29) Three of the studies also added bevacizumab.”
BackgroundKhot, M. I., Andrew, H., Svavarsdottir, H. S., Armstrong, G., Quyn, A. J., & Jayne, D. G. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.001 · Cited by 72
Saltz, L. B., Badarinath, S., Dakhil, S. R., Bienvenu, B. J., Harker, W. G., Birchfield, G., Tokaz, L. K., Barrera, D., Conkling, P., O’Rourke, M. A., et al. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.05.006 · Cited by 72
Methods of overcoming treatment resistance in colorectal cancer
Temraz, S. N., Mukherji, D., Alameddine, R. S., & Shamseddine, A. I. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.015 · Cited by 75
“Some studes support the use of cetuximab in the first line treatment of CRC in combination with chemotherapy regimens [31,32].”
BackgroundThe ethical use of mandatory research biopsies
Olson, E. M., Lin, N., Krop, I. E., & Winer, E. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.114 · Cited by 72
Ishii, Y., Hasegawa, H., Endo, T., Okabayashi, K., Ochiai, H., Moritani, K., Watanabe, M., & Kitagawa, Y. (2010) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2010.05.017 · Cited by 71
Personalized medicine: hope or hype?
Salari, K., Watkins, H., & Ashley, E. A. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs112 · Cited by 70
Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review
Baas, J. M., Krens, L. L., Guchelaar, H., Ouwerkerk, J., de Jong, F. A., Lavrijsen, A. P. M., & Gelderblom, H. A. J. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.09.004 · Cited by 69
Giessen, C. A., Laubender, R. P., Ankerst, D. P., Stintzing, S., Modest, D. P., Mansmann, U., & Heinemann, V. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1515 · Cited by 76
Hoekstra, E., Das, A. M., Swets, M., Cao, W., van der Woude, C. J., Bruno, M. J., Peppelenbosch, M. P., Kuppen, P. J. K., ten Hagen, T. L. M., & Fuhler, G. M. (2016) · Oncotarget · doi:10.18632/oncotarget.7829 · Cited by 73
Kim, E. S., Neubauer, M., Cohn, A. L., Schwartzberg, L. S., Garbo, L. E., Caton, J. R., Robert, F., Reynolds, C. H., Katz, T. L., Chittoor, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70473-x · Cited by 74
EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1
Ando, T., Arang, N., Wang, Z., Costea, D. E., Feng, X., Goto, Y., Izumi, H., Gilardi, M., Ando, K., & Gutkind, J. S. (2021) · Communications Biology · doi:10.1038/s42003-021-02744-4 · Cited by 74
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 74
Correale, P., Marra, M., Remondo, C., Migali, C., Misso, G., Arcuri, F. P., Del Vecchio, M. T., Carducci, A., Loiacono, L., Tassone, P., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.005 · Cited by 67
Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer
Henry, J. T., Coker, O., Chowdhury, S., Shen, J. P., Morris, V. K., Dasari, A., Raghav, K., Nusrat, M., Kee, B., Parseghian, C., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00256 · Cited by 66
Kuo, Y., Chen, J., Fan, C., Li, Y.-S., & Chan, E. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.03.024 · Cited by 73
The unique immune microenvironment of liver metastases: Challenges and opportunities
Ciner, A., Jones, K. I., Muschel, R. J., & Brodt, P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.003 · Cited by 79
Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., Grob, T., Alawi, M., Indenbirken, D., Kriegs, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3574 · Cited by 67
“For the treatment of metastatic colorectal cancer (mCRC) the chimeric EGFR antibody cetuximab and the fully human antibody panitumumab were approved as single agents or in combination with chemotherapy [1-11].”
BackgroundThe molecular therapy of colorectal cancer
Waldner, M. J., & Neurath, M. F. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.02.005 · Cited by 77
Safety and feasibility of targeted agent combinations in solid tumours
Park, S. R., Davis, M., Doroshow, J. H., & Kummar, S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.245 · Cited by 73
Vincenzi, B., Galluzzo, S., Santini, D., Rocci, L., Loupakis, F., Correale, P., Addeo, R., Zoccoli, A., Napolitano, A., Graziano, F., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq550 · Cited by 67
“There is ample evidence that benefit of cetuximab is limited to patients with KRAS wild-type tumors [13].”
Mekenkamp, L. J., Tol, J., Dijkstra, J. R., de Krijger, I., Vink-Börger, M. E., van Vliet, S., Teerenstra, S., Kamping, E., Verwiel, E., Koopman, M., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-292 · Cited by 66
“; licensee BioMed Ce Creative Commons Attribution License (http:/ distribution, and reproduction in any medium monotherapy [1,2] and when added to chemotherapy [3,4].”
BackgroundRoukos, D. H. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.10 · Cited by 66
Olivatto, L. O., Vieira, F. M. D. A. C., Pereira, B. V., Victorino, A. P., Bezerra, M. L., Araújo, C. M., Erlich, F., Faroni, L. D., Castro, L., Lusis, E. C., et al. (2013) · Cancer · doi:10.1002/cncr.28045 · Cited by 66
Improving Immunotherapy Through Glycodesign
Buettner, M. J., Shah, S. R., Saeui, C. T., Ariss, R., & Yarema, K. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02485 · Cited by 70
Engineering tumor vasculature on an injection-molded plastic array 3D culture (IMPACT) platform
Lee, S., Lim, J., Yu, J., Ahn, J., Lee, Y., & Jeon, N. L. (2019) · Lab on a Chip · doi:10.1039/c9lc00148d · Cited by 65
Shinozaki, E., Yoshino, T., Yamazaki, K., Muro, K., Yamaguchi, K., Nishina, T., Yuki, S., Shitara, K., Bando, H., Mimaki, S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.308 · Cited by 65
“REFERENCES Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.”
InfluentialStopfer, L. E., Flower, C. T., Gajadhar, A. S., Patel, B., Gallien, S., Lopez-Ferrer, D., & White, F. M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3804 · Cited by 66
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
Ros, J., Baraibar, I., Sardo, E., Mulet-Margalef, N., Salvà, F., Argilés, G., Martini, G., Ciardiello, D., Cuadra‐Urteaga, J. L., Tabernero, J. M., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992974 · Cited by 76
Maßmann, A., Rodt, T., Marquardt, S., Seidel, R., Thomas, K., Wacker, F. K., Richter, G. M., Kauczor, H., Bücker, A., Pereira, P. L., et al. (2015) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-015-1308-9 · Cited by 67
Predictive and Prognostic Markers in Colorectal Cancer
George, B., & Kopetz, S. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0162-3 · Cited by 71
“The lack of efficacy and even a possible detrimental effect to anti-EGFR–based chemotherapy in KRAS-mutated patients have been suggested by the OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) [60 ]a nd CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metast…”
BackgroundNovel Points of Attack for Targeted Cancer Therapy
Røsland, G. V., & Engelsen, A. S. T. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12313 · Cited by 78
Management of stage IV rectal cancer: Palliative options
Ronnekleiv‐Kelly, S. M., & Kennedy, G. D. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i7.835 · Cited by 73
Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis
Bhise, N. S., Shmueli, R. B., Sunshine, J. C., Tzeng, S. Y., & Green, J. J. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.558082 · Cited by 65
“Tarrytown, NY) [28] Binds/sequesters VEGF-A and PLGF Fusion protein Wet AMD Cetuximab (Erbitux , is a registered trademark of ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY) [29,30] Anti-EGFR Chimeric IgG1 mAb mCRC, head and neck cancer in KRAS-wt patients”
BackgroundKim, S. Y., Hong, Y. S., Kim, D. Y., Kim, T. W., Kim, J. H., Im, S.-A., Lee, K. S., Yun, T., Jeong, S., Choi, H. S., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.035 · Cited by 66
Hung, L.-Y., Wang, C., Che, Y.-J., Fu, C.-Y., Chang, H., Wang, K., & Lee, G. (2015) · Scientific Reports · doi:10.1038/srep10326 · Cited by 65
Evidence-based Clinical Management of Acute Malignant Colorectal Obstruction
Shimura, T., & Joh, T. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000475 · Cited by 70
Duwe, G., Knitter, S., Pesthy, S., Beierle, A. S., Bahra, M., Schmelzle, M., Schmuck, R. B., Lohneis, P., Raschzok, N., Öllinger, R., et al. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.05.008 · Cited by 69
Development of Antibody Therapeutics against Flaviviruses
Sun, H., Chen, Q., & Lai, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010054 · Cited by 71
“Such mAb-tumor antigen interactions can activate or block certain downstream signaling pathways and, in turn, reduce tumor cell proliferation or induce tumor cell apoptosis [24,25].”
BackgroundWang, Z.-M., Chen, Y.-Y., Chen, F. F., Wang, S.-Y., & Xiong, B. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.05.020 · Cited by 66
Matsuda, A., Matsumoto, S., Seya, T., Matsutani, T., Kishi, T., Yokoi, K., Wang, P., & Uchida, E. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2972-z · Cited by 67
Vijayaraghavan, A., Efrusy, M. B., Göke, B., Kirchner, T., Santas, C. C., & Goldberg, R. M. (2011) · International Journal of Cancer · doi:10.1002/ijc.26400 · Cited by 69
“Approximately 40% of mCRC tumors have these KRAS gene mutations.(4,10,11) Current U.”
BackgroundLin, Y., Chen, K., Chen, C., Cheng, A., & Chen, K.-F. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.01.012 · Cited by 71
Exosomes promote cetuximab resistance via the PTEN/Akt pathway in colon cancer cells
Zhang, S., Zhang, Y., Qu, J., Che, X., Fan, Y., Hou, K., Guo, T., Deng, G., Song, N., Li, C., et al. (2018) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20176472 · Cited by 63
“However, only a subgroup of individuals with KRAS wildtype cancer benefit from C225 treatment, suggesting the existence of other drug resistance mechanisms, in addition to KRAS gene mutation (2,3).”
BackgroundHe, H., Liu, L., Liang, R., Zhou, H., Pan, H., Zhang, S., & Cai, L. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.01.012 · Cited by 64
Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice
Fassan, M., Scarpa, A., Remo, A., Maglio, G. D., Troncone, G., Marchetti, A., Doglioni, C., Ingravallo, G., Perrone, G., Parente, P., et al. (2020) · Pathologica · doi:10.32074/1591-951x-158 · Cited by 68
Bolhuis, K., Kos, M., van Oijen, M. G. H., Swijnenburg, R., & Punt, C. J. A. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.037 · Cited by 70
The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting
Sun, M., Wang, T., Li, L., Li, X., Zhai, Y., Zhang, J., & Li, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.702445 · Cited by 74
Prognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer
Martelli, V., Pastorino, A., & Sobrero, A. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108239 · Cited by 73
Igarashi, H., Kurihara, H., Mitsuhashi, K., Ito, M., Okuda, H., Kanno, S., Naito, T., Yoshii, S., Takahashi, H., Kusumi, T., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4264-7 · Cited by 67
Skin toxicities of targeted therapies
Segaert, S., Chiritescu, G., Lemmens, L., Dumon, K., Cutsem, E. V., & Tejpar, S. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70044-9 · Cited by 64
Self-citationFiorentino, M., Altimari, A., Maglio, G. D., Gruppioni, E., Capizzi, E., de Biase, D., Degiovanni, A., D’Errico, A., Pession, A., Pizzolitto, S., et al. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s42369 · Cited by 66
“Introduction Monoclonal antibodies against the epidermal growth factor receptor (EGFR) in combination with chemotherapy represent the first example of targeted therapy in colorectal cancer.(1) The KRAS oncogene is a component of the mitogen-activated protein kinase signal transduction pathway downstream of EGFR.”
BackgroundScartozzi, M., Mandolesi, A., Giampieri, R., Bittoni, A., Pierantoni, C., Zaniboni, A., Galizia, E., Giustini, L., Silva, R. R., Bisonni, R., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0119 · Cited by 63
Molecular therapy of colorectal cancer: Progress and future directions
Weng, W., Feng, J., Qin, H., & Ma, Y. (2014) · International Journal of Cancer · doi:10.1002/ijc.28722 · Cited by 67
“cetuximab was limited to patients with KRAS wild-type tumors.(47) Furthermore, a novel mixture of antibody Sym004 provide an alternative therapy force tuxiamab resistance CRC.”
BackgroundRadioimmunotherapy of Solid Tumors: Searching for the Right Target
Hong, S., & Sgouros, G. (2010) · Current Drug Delivery · doi:10.2174/156720111793663651 · Cited by 64
“9 m 2 on average for men) initial dose and 250 mg/m 2 weekly for the duration of the study to treat colorectal cancer [40], while in clinical studies of anti-EGFR antibody radioimmunotherapy, three fractionized injection of 3.”
Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells
Suman, S., Das, T. P., Sirimulla, S., Alatassi, H., Ankem, M. K., & Damodaran, C. (2016) · Oncotarget · doi:10.18632/oncotarget.7351 · Cited by 63
18F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status
Lovinfosse, P., Koopmansch, B., Lambert, F., Jodogne, S., Kustermans, G., Hatt, M., Visvikis, D., Seidel, L., Polus, M., Albert, A., et al. (2016) · The British Journal of Radiology · doi:10.1259/bjr.20160212 · Cited by 63
Passot, G., Denbo, J. W., Yamashita, S., Kopetz, S., Chun, Y. S., Maru, D. M., Overman, M. J., Brudvik, K. W., Conrad, C. H., Aloia, T. A., et al. (2016) · Surgery · doi:10.1016/j.surg.2016.07.032 · Cited by 64
EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
Okada, Y., Kimura, T., Nakagawa, T., Okamoto, K., Fukuya, A., Goji, T., Fujimoto, S., Sogabe, M., Miyamoto, H., Muguruma, N., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0383 · Cited by 62
“For patients with metastatic CRC (mCRC), two mAbs targeting EGFR, cetuximab and panitumumab, have been proven to be effective in combination with chemotherapy or as monotherapy (10-15).”
Takahashi, N., Yamada, Y., Furuta, K., Honma, Y., Iwasa, S., Takashima, A., Kato, K., Hamaguchi, T., & Shimada, Y. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.230 · Cited by 66
“AntiEGFR monoclonal antibodies are active drugs, and gene mutations of KRAS codons 12 and 13 are recognised as strong predictive factors for no clinical benefit of anti-EGFR antibody treatment in mCRC (Jonker et al, 2007; Van Cutsem et al, 2009; Douillard et al, 2010).”
BackgroundJones, R. P., Hamann, S., Malik, H., Fenwick, S. W., Poston, G. J., & Folprecht, G. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.02.024 · Cited by 63
“[6]”
BackgroundSelf-citationAyez, N., van der Stok, E. P., Wilt, H. D., Radema, S. A., van Hillegersberg, R., Roumen, R. M. H., Vreugdenhil, G., Tanis, P. J., Punt, C. J. A., Dejong, C. H. C., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1199-8 · Cited by 62
Yoshino, T., Muro, K., Yamaguchi, K., Nishina, T., Denda, T., Kudo, T., Okamoto, W., Taniguchi, H., Akagi, K., Kajiwara, T., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.007 · Cited by 63
“(Amado et al., 2008; Bokemeyer et al., 2009; Douillard et al., 2010; Lièvre et al., 2006; Van Cutsem et al., 2009).”
McWhirter, D., Kitteringham, N. R., Jones, R. P., Malik, H., Park, K., & Palmer, D. H. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.011 · Cited by 64
Colon cancer and the elderly: From screening to treatment in management of GI disease in the elderly
Holt, P. R., Kozuch, P. S., & Mewar, S. (2009) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2009.10.010 · Cited by 75
Hainsworth, J. D., Spigel, D. R., Thompson, D. S., Murphy, P. B., Lane, C. M., Waterhouse, D. M., Naot, Y., & Greco, F. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0112 · Cited by 62
An update on chemotherapy of colorectal liver metastases
Wang, C., & Li, J. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i1.25 · Cited by 63
Oki, E., Emi, Y., Yamanaka, T., Uetake, H., Muro, K., Takahashi, T., Nagasaka, T., Hatano, E., Ojima, H., Manaka, D., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0518-2 · Cited by 63
Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer
Asghar, U. S., Hawkes, E. A., & Cunningham, D. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.040 · Cited by 67
Oncologic Imaging: A Guiding Hand of Personalized Cancer Care
Hricak, H. (2011) · Radiology · doi:10.1148/radiol.11110252 · Cited by 61
Saridaki, Z., Weidhaas, J. B., Lenz, H., Laurent‐Puig, P., Jacobs, B., Schutter, J. D., Roock, W. D., Salzman, D. W., Zhang, W., Yang, D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0348 · Cited by 68
“Nevertheless, their efficacy is restricted to a subset of patients, as non-randomized retrospective studies (6-9), retrospective analysis of prospective randomized trials (10-13), a summary of the above mentioned publications and a grand European consortium study (14) have demonstrated.”
BackgroundSelf-citationPersonalized Medicine: Four Perspectives of Tailored Medicine
Ruberg, S. J., & Shen, L. (2015) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2015.1059354 · Cited by 64
Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Garcia-Ruiz, C., Morales, A., & Fernandez-Checa, J. C. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012800228715 · Cited by 61
“cetuximab and panitumumab) that target the epidermal growth factor receptor (EGFR) are effective in terms of response rate and progressionfree survival in combination with standard cytotoxic chemotherapy in metastatic CRC [94,95].”
BackgroundPrognostic Role of KRAS, NRAS, BRAF and PIK3CA Mutations in Advanced Colorectal Cancer
Foltran, L., Maglio, G. D., Pella, N., Ermacora, P., Aprile, G., Masiero, E., Giovannoni, M., Iaiza, E., Cardellino, G. G., Lutrino, S. E., et al. (2015) · Future Oncology · doi:10.2217/fon.14.279 · Cited by 72
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
Nigro, C. L., Ricci, V., Vivenza, D., Granetto, C., Fabozzi, T., Miraglio, E., & Merlano, M. C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6944 · Cited by 70
Costa, C. O. D., Honorato, J., Baliza, I. R. S., Dias, R. B., Valverde, L. D. F., Vidal, M. T. A., Sales, C. B. S., Rocha, C. A. G., Moreira, D. R. M., Soares, M. B. P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22248 · Cited by 64
Expanded RAS: Refining the Patient Population
Atreya, C. E., Corcoran, R. B., & Kopetz, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9325 · Cited by 63
“The epidermal growth factor receptor (EGFR) antibody cetuximab was first approved a decade ago for use with FOLFIRI (folinic acid, fluorouracil, and irinotecan) chemotherapy in metastatic CRC (mCRC), based on the findings of the CRYSTAL (Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorecta…”
BackgroundHecht, J. R., Douillard, J., Schwartzberg, L. S., Grothey, A., Kopetz, S., Rong, A., Oliner, K. S., & Sidhu, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.008 · Cited by 68
“The CRYSTAL study randomly assigned 1198 patients with EGFR-positive mCRC to cetuximab plus FOLFIRI or FOLFIRI alone.(24) When treatment outcomes were analyzed according to RAS mutation status, KRAS and NRAS mutational status was confirmed to be strongly predictive for the efficacy of cetuximab plus FOLFIRI: mutations…”
MethodCetuximab in the treatment of patients with colorectal cancer
Garrett, C. R., & Eng, C. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.582464 · Cited by 66
“A randomized, Phase III study (the ‘CRYSTAL’ trial) evaluated 1198 patients treated with infusional and bolus 5-fluoruracil/leucovorin chemotherapy plus irinotecan (FOLFIRI chemotherapy) either with or without cetuximab therapy; this study fulfilled the primary end point of improvement in PFS in favor of the cetuximab…”
MethodChung, C. H., Seeley, E. H., Röder, H., Grigorieva, J., Tsypin, M., Roder, J., Burtness, B. A., Argiris, A. E., Forastiere, A. A., Gilbert, J., et al. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0937 · Cited by 61
Impact of primary colorectal Cancer location on the KRAS status and its prognostic value
Xie, M., Li, J., Cai, Z.-M., Li, K., & Hu, B.-L. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-0965-5 · Cited by 70
Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer
Koulis, C., Yap, R. J., Engel, R. M., Jardé, T., Wilkins, S., Solon, J. G., Shapiro, J. D., Abud, H. E., & McMurrick, P. J. (2020) · Cancers · doi:10.3390/cancers12040812 · Cited by 64
Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review
de Mestier, L., Manceau, G., Neuzillet, C., Bachet, J., Spano, J., Kianmanesh, R., Vaillant, J. C., Bouché, O., Hannoun, L., & Karoui, M. (2014) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v6.i6.156 · Cited by 66
Cetuximab and chemoradiation for rectal cancer–is the water getting muddy?
Glynne‐Jones, R., Mawdsley, S., & Harrison, M. (2010) · Acta Oncologica · doi:10.3109/02841860903536010 · Cited by 64
“In the fi rst-line metastatic setting there appears an advantage when cetuximab is added to regimens containing irinotecan [7], but not always oxaliplatin [9].”
BackgroundZeng, X., Yang, P., Chen, B., Jin, X., Liu, Y., Zhao, X., & Liang, S. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.05.032 · Cited by 67
“cancer (CRC), also known as colon cancer, is the third most common cancer worldwide, and one fourth of the patients with CRChave an occurrence ofmetastasis and a 5 year survival rate of <10% [15].”
BackgroundKrebs, M., Renehan, A. G., Backen, A. C., Gollins, S., Chau, I., Hasan, J., Valle, J. W., Morris, K. L., Beech, J., Ashcroft, L., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.006 · Cited by 61
Souglakos, J., Ziras, N., Kakolyris, S., Boukovinas, I., Kentepozidis, N., Makrantonakis, P., Xynogalos, S., Christophyllakis, C., Kouroussis, C., Vamvakas, L., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.594 · Cited by 60
Bhangu, A. A., Wood, G., Mirnezami, A. H., Darzi, A. W., Tekkis, P. P., & Goldin, R. D. (2012) · Surgical Oncology · doi:10.1016/j.suronc.2012.08.003 · Cited by 65
“KRAS mutations are present in approximately 40% of patients with metastatic colorectal cancers [15].”
BackgroundNanofluidic Digital PCR for KRAS Mutation Detection and Quantification in Gastrointestinal Cancer
Azuara, D., Morell, M., Gausachs, M., Rodríguez‐Moranta, F., Fabregat, J., Busquets, J., Peláez, N., Boadas, J., Galter, S., Moreno, V. R., et al. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.186577 · Cited by 65
Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes
Massalou, D., Benizri, E. I., Chevallier, A., Duranton‐Tanneur, V., Pédeutour, F., Benchimol, D., & Béréder, J.-M. (2016) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2016.03.008 · Cited by 61
Zellweger, M., Abdelnour‐Berchtold, E., Krueger, T., Ris, H., Perentes, J. Y., & González, M. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.05.001 · Cited by 65
Mizukami, T., Izawa, N., Nakajima, T. E., & Sunakawa, Y. (2019) · Drugs · doi:10.1007/s40265-019-01113-0 · Cited by 65
The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer
He, Z., Thorrez, L., Siegfried, G., Meulemans, S. M. P., Évrard, S., Tejpar, S., Khatib, A., & Creemers, J. W. M. (2020) · Oncogene · doi:10.1038/s41388-020-1238-z · Cited by 62
Self-citationEsophagogastric cancer: Targeted agents
Ku, G. Y., & Ilson, D. H. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.009 · Cited by 63
Lin, Y., Paolucci, I., Brock, K. K., & Odisio, B. C. (2021) · Cancers · doi:10.3390/cancers13163926 · Cited by 63
Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature
Guo, M. Z., Jin, N. Y., Pawlik, T. M., & Cloyd, J. M. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i9.1043 · Cited by 62
Metadata
- Authors
- Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., Roh, J. K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., & Rougier, P.
- Affiliations
- Klinikum Oldenburg (DE)
- Moscow City Oncology Hospital №62 (RU)
- Petz Aladár Megyei Oktató Kórház (HU)
- National University Hospital (SG)
- Yonsei University (KR)
- University Hospital Carl Gustav Carus (DE)
- University of the Witwatersrand (ZA)
- Merck KGaA, Darmstadt (Germany) (DE)
- Universitair Ziekenhuis Leuven (BE)
- Hôpital Ambroise-Paré (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-04-02
- Volume
- 360
- Issue
- 14
- Pages
- 1408-1417
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095201384
- Cited by
- 3,877
- References
- 34
- Citations by year
- 2026: 83 · 2025: 87 · 2024: 105 · 2023: 136 · 2022: 169 · 2021: 173 · 2020: 194 · 2019: 199 · 2018: 172 · 2017: 221 · 2016: 275 · 2015: 307 · 2014: 337 · 2013: 328 · 2012: 331
- FWCI
- 179.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- cetuximab, FOLFIRI, metastatic colorectal cancer, first-line therapy, KRAS mutation status, epidermal growth factor receptor, progression-free survival, overall survival, treatment response, adverse events, irinotecan, 5-fluorouracil, leucovorin, skin reactions, diarrhea, infusion reactions, anti-EGFR therapy
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Disease Progression, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.